Safety Study of MG1102 in Patients With Solid Tumors
Status:
Terminated
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
To investigate the safety and tolerability of a 28 day course of intravenous (IV) MG1102 in
patients with solid tumors for which no standard therapy is available.